Artificial intelligence to be used for the detection of common eye disease
Dry Eye Disease (DED) is one of the more common eye diseases, affecting up to 30% of the world’s population. This disease can affect many different types of… read more.
Dry Eye Disease (DED) is one of the more common eye diseases, affecting up to 30% of the world’s population. This disease can affect many different types of… read more.
NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay… read more.
The FDA has approved clobetasol propionate ophthalmic suspension 0.05% (APP 13007) by Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics. This suspension for the treatment of post-operative inflammation and pain… read more.
New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease. The University of Bristol-led research is… read more.
A new study suggests a naturally-occurring material is an effective disinfectant for contact lenses, worn by millions of people worldwide. Microbial keratitis is one of the most serious… read more.
Genentech, a member of the Roche Group announced new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to… read more.
A new study has found there is significant scope to increase the number of eye donations from patients cared for in hospice and palliative care settings – donations… read more.
LianBio a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced topline results from the Phase III LIBRA clinical trial… read more.
A new compound developed at the University of Illinois Chicago potentially could offer an alternative to injections for the millions of people who suffer from an eye condition… read more.
Novartis announced that it has completed its divestment of ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up… read more.
The FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for the treatment of adult… read more.
New research from the University of Gothenburg has found that preterm babies given a supplement with a combination of omega-3 and omega-6 fatty acids have better visual function… read more.
Advertisment